Table 2.
Exposure of patients to pharmacogenomic (PGx) drugs over available prescribing periods
| Available prescribing periods | Before 1 January 2013 | After 1 January 2013 | ||
|---|---|---|---|---|
| 2 years (2011–2012) | 10 years (2003–2012) | 20 years (1993–2012) | 5 years (2013–2017) | |
| Total practices with complete recording throughout period | 215 | 215 | 159 | 82 |
| Total patients registered throughout period | 684 141 | 538 602 | 289 186 | 203 395 |
| ‐ with ≥1 prescription for any drug, n (%) | 596 767 (87%) | 517 843 (96%) | 283 948 (98%) | 190 035 (93%) |
| ‐ with ≥1 prescription for any PGx drug, n (%) | 399 311 (58%) | 400 422 (74%) | 231 113 (80%) | 143 947 (71%) |
| PGx drugs | ||||
| ‐ mean per patient | 1.2 | 2.1 | 2.5 | 1.7 |
| ‐ median (interquartile range) | 1 (0–2) | 2 (0–3) | 2 (1–4) | 1 (0–3) |
| Number of patients with multiple PGx drugs | ||||
| ‐ with ≥2 PGx drugs, n (%) | 222 796 (33%) | 284 238 (53%) | 172 818 (60%) | 95 454 (47%) |
| ‐ with ≥5 PGx drugs, n (%) | 17 879 (3%) | 67 465 (13%) | 50 769 (18%) | 14 448 (7%) |